STOCK TITAN

Johnson & Johnson highlights innovative neuropsychiatry portfolio and pipeline at Psych Congress

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags

Johnson & Johnson (NYSE: JNJ) announced the presentation of 23 abstracts featuring new real-world and clinical trial data from its neuropsychiatry portfolio at Psych Congress. Key highlights include five-year safety data from 35,000 adults treated with SPRAVATO®, insights into anhedonia in major depressive disorder (MDD), and an analysis of over 30,000 adults with schizophrenia examining the link between symptom relapse and mortality risk. The presentations cover treatment-resistant depression, MDD, and schizophrenia, showcasing data on SPRAVATO®'s long-term safety and efficacy, as well as insights from the company's long-acting injectable portfolio.

Johnson & Johnson (NYSE: JNJ) ha annunciato la presentazione di 23 abstract contenenti nuovi dati reali e provenienti da studi clinici del suo portafoglio di neuropsichiatria al Psych Congress. Tra i punti salienti ci sono i dati di sicurezza quinquennali su 35.000 adulti trattati con SPRAVATO®, approfondimenti sull'anedonia nel disturbo depressivo maggiore (MDD) e un'analisi di oltre 30.000 adulti con schizofrenia che esamina il legame tra la ricaduta dei sintomi e il rischio di mortalità. Le presentazioni riguardano la depressione resistente al trattamento, il MDD e la schizofrenia, mettendo in mostra dati sulla sicurezza e l'efficacia a lungo termine di SPRAVATO®, oltre a intuizioni dal portafoglio di iniettabili a lungo termine dell'azienda.

Johnson & Johnson (NYSE: JNJ) anunció la presentación de 23 resúmenes que presentan nuevos datos del mundo real y de ensayos clínicos de su cartera de neuropsiquiatría en el Psych Congress. Los aspectos más destacados incluyen datos de seguridad a cinco años de 35,000 adultos tratados con SPRAVATO®, información sobre la anhedonia en el trastorno depresivo mayor (TDM) y un análisis de más de 30,000 adultos con esquizofrenia que examina la relación entre la recaída de síntomas y el riesgo de mortalidad. Las presentaciones abarcan la depresión resistente al tratamiento, el TDM y la esquizofrenia, mostrando datos sobre la seguridad y eficacia a largo plazo de SPRAVATO®, así como perspectivas del portafolio inyectable de acción prolongada de la empresa.

존슨앤드존슨 (NYSE: JNJ)은 Psych Congress에서 신경정신과 포트폴리오의 새로운 실제 및 임상시험 데이터를 포함한 23개의 초록을 발표했습니다. 주요 하이라이트는 35,000명의 성인에 대한 5년 안전성 데이터, 주요 우울 장애(MDD)에서의 무기력증 통찰력, 그리고 정신분열증을 앓고 있는 30,000명 이상의 성인을 대상으로 한 증상 재발과 사망 위험 간의 연관성 분석을 포함합니다. 발표 내용은 치료 저항성 우울증, MDD 및 정신분열증을 포함하며 SPRAVATO®의 장기 안전성 및 효능에 대한 데이터와 회사의 장기 작용 주사제 포트폴리오에 대한 통찰력을 보여줍니다.

Johnson & Johnson (NYSE: JNJ) a annoncé la présentation de 23 résumés présentant de nouvelles données du monde réel et des essais cliniques provenant de son portefeuille de neuropsychiatrie lors du Psych Congress. Les points clés incluent des données de sécurité sur cinq ans de 35 000 adultes traités avec SPRAVATO®, des informations sur l'anédonie dans le trouble dépressif majeur (TDM) et une analyse de plus de 30 000 adultes atteints de schizophrénie examinant le lien entre la rechute des symptômes et le risque de mortalité. Les présentations couvrent la dépression résistante au traitement, le TDM et la schizophrénie, mettant en avant des données sur la sécurité et l'efficacité à long terme de SPRAVATO®, ainsi que des informations sur le portefeuille injectable à action prolongée de l'entreprise.

Johnson & Johnson (NYSE: JNJ) gab die Präsentation von 23 Abstracts bekannt, die neue Real-World- und klinische Studiendaten aus seinem neuropsychiatrischen Portfolio auf dem Psych Congress zeigen. Zu den wichtigsten Highlights gehören fünfjährige Sicherheitsdaten von 35.000 Erwachsenen, die mit SPRAVATO® behandelt wurden, Erkenntnisse zur Anhedonie bei Major Depression Disorder (MDD) sowie eine Analyse von über 30.000 Erwachsenen mit Schizophrenie, die den Zusammenhang zwischen Symptommuster und Sterblichkeitsrisiko untersucht. Die Präsentationen behandeln therapieresistente Depression, MDD und Schizophrenie und zeigen Daten zur langfristigen Sicherheit und Wirksamkeit von SPRAVATO® sowie Erkenntnisse aus dem Portfolio der langwirksamen injizierbaren Medikamente des Unternehmens.

Positive
  • Five-year real-world safety data from 35,000 patients reinforces SPRAVATO®'s consistent safety profile
  • Large-scale analysis (30,000+ patients) provides valuable insights into schizophrenia treatment outcomes
  • Comprehensive data presentation across multiple psychiatric conditions strengthens J&J's position in neuropsychiatry
Negative
  • None.

Insights

The presentation of 23 abstracts at Psych Congress represents significant clinical validation for J&J's neuropsychiatry portfolio. The 5-year safety data from 35,000 SPRAVATO® patients provides robust evidence supporting the drug's long-term safety profile in treatment-resistant depression. This extensive real-world validation strengthens SPRAVATO®'s market position.

The analysis linking schizophrenia relapse to mortality risk in over 30,000 patients could drive increased adoption of long-acting injectables like paliperidone palmitate. The data showing 15-20% premature mortality highlights an urgent medical need and market opportunity.

The breadth of research across depression and schizophrenia, particularly around anhedonia and insomnia symptoms, demonstrates J&J's commitment to expanding therapeutic applications. This pipeline development and real-world evidence generation should help maintain J&J's leadership in neuropsychiatry.

  • New five-year data reinforce long-term safety and efficacy of SPRAVATO® (esketamine) in patients with inadequate response to two or more oral antidepressants (treatment-resistant depression)  
  • 23 abstracts highlight data from Company's robust portfolio and pipeline, including clinical insights on major depressive disorder and the significant burden of anhedonia and insomnia symptoms
  • Large real-world analysis highlights the link between reducing relapse and improving survival in schizophrenia

TITUSVILLE, N.J., Oct. 24, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today that 23 abstracts featuring new real-world and clinical trial data from across its neuropsychiatry portfolio and pipeline will be presented at the annual U.S. Psychiatric and Mental Health Congress (Psych Congress), taking place October 29 to November 2 in Boston, Massachusetts. Presentations include new data supporting the safety and efficacy of SPRAVATO® (esketamine) CIII nasal spray and the Company's innovative portfolio of long-acting injectables (LAIs) for schizophrenia, as well as data highlighting the significant burden people living with major depressive disorder (MDD) and schizophrenia often face.

"For nearly seven decades, J&J has been at the forefront of driving scientific progress and innovation in neuroscience," said Bill Martin, Ph.D., Global Neuroscience Therapeutic Area Head, Johnson & Johnson Innovative Medicine. "It is our responsibility and privilege to help advance research and understanding of MDD and schizophrenia so we can continue to deliver transformational therapies that address the greatest unmet patient needs."

Key presentations include:

  • New five-year, real-world safety data from nearly 35,000 adults treated with SPRAVATO®, building on more than a decade of research and reinforcing its well-studied, consistent safety profile (Poster 151).
  • Novel insights into the clinical, humanistic and economic burden of anhedonia in adults with MDD (Poster 113).
  • Results from an analysis of more than 30,000 adults with schizophrenia highlighting the link between symptom relapse and risk of death, which can occur 15‐20 years prematurely for adults living with schizophrenia compared to the general population due to many different causes.1 (Poster 42).

"Serious mental illness is one of the most complex health challenges of our time," said Pearl Pugh, President, U.S. Neuroscience, Johnson & Johnson Innovative Medicine. "Understanding the patient experience is at the core of our mission to develop breakthrough solutions that can help improve care and make a difference in the lives of those living with challenging-to-treat mental illnesses."

J&J will present the following posters at Psych Congress on October 31 from 1:30-3:30 p.m. ET and November 1 from 1:30-3:30 p.m. ET in the Exhibit Hall.

Poster #

Title 

Treatment-Resistant Depression

151

Real-World Safety Profile of Esketamine Nasal Spray: An Analysis of the Risk Evaluation and Mitigation Strategy Program Approximately 5 Years After Approval in the United States

112

Efficacy and Safety of Esketamine Nasal Spray as Monotherapy in Adults with Treatment-Resistant Depression: A Randomized, Double-Blind, Placebo-Controlled Study

102

Weight and Metabolic Changes in Patients Treated with Esketamine Nasal Spray Versus Quetiapine Extended Release: A Post Hoc Subgroup Analysis of the ESCAPE-TRD Study

200

Clinical Effectiveness and Persistence on Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Overall and Among Transcranial Magnetic Stimulation-Naïve Subgroup

202

Response and Remission on Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Overall and Among TMS-Naive Subgroup

203

Comparison of Real-World Response and Remission Among Patients with Treatment-Resistant Depression Treated with Esketamine Nasal Spray or Antipsychotic Augmentation

201

Real-World Clinical Effectiveness of Esketamine Nasal Spray Based on the Montgomery-Åsberg Depression Rating Scale (MADRS) Among Patients with Treatment-Resistant Depression in the United States

148

Trajectory of Response and Remission in Induction Nonresponders to Esketamine Nasal Spray: A Subgroup Analysis of the SUSTAIN-3 Study

Major Depressive Disorder

113

Higher Anhedonia Is Associated with Poorer Clinical and Humanistic Outcomes Among U.S. Adults with Major Depressive Disorder

124

Seltorexant, Adjunctive to Antidepressants, in Adults with Major Depressive Disorder with Insomnia Symptoms: Results of a Double-Blind, Randomized, Placebo-Controlled Study 

206

Adjunctive Treatment with Seltorexant Improved Patient-Reported Depressive Symptoms, Insomnia Symptoms, and Overall Health in Major Depressive Disorder with Insomnia

59

Pharmacokinetics and Safety of Seltorexant, Selective Orexin-2 Receptor Antagonist, in Healthy Elderly and Young Non-Asian, and Japanese Adult Participants

145

Major Depressive Disorder with Clinically Relevant Insomnia Symptoms: Healthcare Professional Assessment of Patient Impact and Clinical Management 

146

Treating Insomnia Symptoms as Part of Major Depressive Disorder: A Cross-Sectional Survey on Patient Needs in the U.S.

186

How Do Patients with Depression and Their Providers Talk About Anhedonia? An Ethnographic Analysis of Healthcare Provider Conversations with Patients in the Clinical Setting

16

Burden of Prominent Anhedonia in Major Depressive Disorder Reflected in Polypharmacy, Healthcare Use, and Humanistic Outcomes

64

Clinical Burden and Treatment Satisfaction in a Real-World Survey of Patients Diagnosed with Major Depressive Disorder (MDD) With Prominent Anhedonia

147

Disease Burden Associated with Prominent Anhedonia in Patients with Major Depressive Disorder (MDD) from Adelphi Depression Disease Specific Program

32

Clinical Burden of Patients Diagnosed with Major Depressive Disorder with versus Without Prominent Anhedonia Using a Real-World Dataset in the United States

Schizophrenia

42

Association of Relapse with All-Cause Mortality in 32,071 Adults with Stable Schizophrenia: A Longitudinal Commercial and Medicare Database Study 

39

Characteristics and Antipsychotic Treatment Pathways of Patients with Schizophrenia Who Received Once-Every-6-Months Paliperidone Palmitate Within the First Two Years of Approval

34

Real-World Comparative Effectiveness of Long-Acting Injectable and Oral Antipsychotics Among U.S. Medicare Beneficiaries with Schizophrenia

103

Symptomatic and Functional Remission with Paliperidone Palmitate 3-Month and 6-Month Formulations in Adult Patients with Schizophrenia: A 3-Year Analysis

ABOUT TREATMENT-RESISTANT DEPRESSION
Depression is a common mental health disorder that impacts an estimated 280 million people worldwide.2 In the U.S., approximately 21 million adults have had at least one major depressive episode, and approximately one-third of medication-treated adults are considered to have TRD.3,4 People living with MDD are often considered to have TRD if they have not responded adequately to at least two different antidepressants of adequate dose and duration in the current depressive episode.4 TRD has a significant negative impact on the lives of those affected and has one of the highest economic burdens of all psychiatric disorders.4

ABOUT SPRAVATO®
SPRAVATO® (esketamine) CIII nasal spray is approved by the U.S. Food and Drug Administration in combination with an oral antidepressant for adults with TRD and depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior. It is the first treatment to use a new mechanism of action in decades for the treatment of TRD. SPRAVATO® is a non-selective, non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor and is believed to work differently by acting on a pathway in the brain that affects glutamate. To date, SPRAVATO® has been approved in 79 countries and administered to more than 100,000 patients worldwide.

ABOUT MAJOR DEPRESSIVE DISORDER WITH INSOMNIA SYMPTOMS
MDD is one of the most common psychiatric disorders and leading causes of disability worldwide,5 with an estimated 280 million people living with the disorder around the world.2 MDD is often accompanied by sleep disturbances such as insomnia or hypersomnia, affecting up to 60 percent of patients with MDD.6 Disturbed sleep and insomnia symptoms have a significant impact on a patient's quality of life and exacerbate the risk of depressive relapse and suicide.7,8

ABOUT SELTOREXANT
Seltorexant, an investigational potential first-in-class therapy, is a selective antagonist of the human orexin-2 receptor currently being developed as an adjunctive treatment for adults with MDD with insomnia symptoms. Seltorexant is believed to selectively antagonize the orexin-2 receptors, potentially improving mood and sleep symptoms associated with depression. When orexin-2 receptors are stimulated for too long or at inappropriate times, their activation can cause hyperarousal manifestations, including insomnia and excessive cortisol release, which may contribute to depression and insomnia.

ABOUT SCHIZOPHRENIA
Schizophrenia is a chronic and severe brain disorder affecting approximately 20 million people worldwide and an estimated 2.4 million adults in the U.S.9-11 The disease is characterized by distortions in thinking, perception, emotions, language, sense of self, and behavior.9 It can also lead to neurological impairment and severe disability.12 Antipsychotic medication is recognized as an essential component in the treatment of schizophrenia, and adherence to medication plays a critical role in controlling symptoms and costly relapses.13

ABOUT J&J'S U.S. LONG-ACTING INJECTABLES
The J&J U.S. portfolio of long-acting injectable treatments for adults with schizophrenia provides the most varied range of dosing options and the longest-lasting schizophrenia treatments with each dose available. Our portfolio includes INVEGA SUSTENNA® (1-month paliperidone palmitate), INVEGA TRINZA® (3-month paliperidone palmitate), and INVEGA HAFYERA® (6-month paliperidone palmitate), all of which are administered in a clinical setting by a medical professional.

Long-acting injectables (LAIs) allow for the slow release of medicine into the bloodstream and have been available and studied for more than 50 years. Based on clinical guidance, the National Council for Mental Wellbeing and the American Psychiatric Association have updated their guidance and practice guidelines to recommend the use of LAIs for appropriate patients.14-16

SPRAVATO® IMPORTANT SAFETY INFORMATION 

What is SPRAVATO® (esketamine) CIII nasal spray? 

SPRAVATO® is a prescription medicine, used along with an antidepressant taken by mouth to treat:

  • Adults with treatment-resistant depression (TRD)
  • Depressive symptoms in adults with major depressive disorder (MDD) with suicidal thoughts or actions

SPRAVATO® is not for use as a medicine to prevent or relieve pain (anesthetic). It is not known if SPRAVATO® is safe or effective as an anesthetic medicine.

It is not known if SPRAVATO® is safe and effective for use in preventing suicide or in reducing suicidal thoughts or actions. SPRAVATO® is not for use in place of hospitalization if your healthcare provider determines that hospitalization is needed, even if improvement is experienced after the first dose of SPRAVATO®.

It is not known if SPRAVATO® is safe and effective in children.

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about SPRAVATO®?

SPRAVATO® can cause serious side effects, including:

  • Sedation and dissociation. SPRAVATO® may cause sleepiness (sedation), fainting, dizziness, spinning sensation, anxiety, or feeling disconnected from yourself, your thoughts, feelings, space and time (dissociation).
    • Tell your healthcare provider right away if you feel like you cannot stay awake or if you feel like you are going to pass out.
    • Your healthcare provider must monitor you for serious side effects for at least 2 hours after taking SPRAVATO®. Your healthcare provider will decide when you are ready to leave the healthcare setting.
  • Respiratory depression was observed with the use of SPRAVATO®; additionally, there were rare reports of respiratory arrest.  
    • Your healthcare provider must monitor you for serious side effects for at least 2 hours (including pulse oximetry) after taking SPRAVATO®. Your healthcare provider will decide when you are ready to leave the healthcare setting.
  • Abuse and misuse. There is a risk for abuse and physical and psychological dependence with SPRAVATO® treatment. Your healthcare provider should check you for signs of abuse and dependence before and during treatment with SPRAVATO®
    • Tell your healthcare provider if you have ever abused or been dependent on alcohol, prescription medicines, or street drugs.
    • Your healthcare provider can tell you more about the differences between physical and psychological dependence and drug addiction. 
  • SPRAVATO® Risk Evaluation and Mitigation Strategy (REMS). Because of the risks for sedation, dissociation, respiratory depression, and abuse and misuse, SPRAVATO® is only available through a restricted program called the SPRAVATO® Risk Evaluation and Mitigation Strategy (REMS) Program. SPRAVATO® can only be administered at healthcare settings certified in the SPRAVATO® REMS Program. Patients treated in outpatient healthcare settings (e.g., medical offices and clinics) must be enrolled in the program.

  • Increased risk of suicidal thoughts and actions. Antidepressant medicines may increase suicidal thoughts and actions in some people 24 years of age and younger, especially within the first few months of treatment or when the dose is changed. SPRAVATO® is not for use in children.
    • Depression and other serious mental illnesses are the most important causes of suicidal thoughts and actions. Some people may have a higher risk of having suicidal thoughts or actions. These include people who have (or have a family history of) depression or a history of suicidal thoughts or actions.
  • How can I watch for and try to prevent suicidal thoughts and actions in myself or a family member?
    • Pay close attention to any changes, especially sudden changes, in mood, behavior, thoughts, or feelings, or if you develop suicidal thoughts or actions.
    • Tell your healthcare provider right away if you have any new or sudden changes in mood, behavior, thoughts, or feelings.
    • Keep all follow-up visits with your healthcare provider as scheduled. Call your healthcare provider between visits as needed, especially if you have concerns about symptoms. 
  • Tell your healthcare provider right away if you or your family member have any of the following symptoms, especially if they are new, worse, or worry you:
    • suicide attempts
    • thoughts about suicide or dying
    • worsening depression
    • other unusual changes in behavior or mood

Do not take SPRAVATO® if you:

  • have blood vessel (aneurysmal vascular) disease (including in the brain, chest, abdominal aorta, arms and legs)
  • have an abnormal connection between your veins and arteries (arteriovenous malformation)
  • have a history of bleeding in the brain
  • are allergic to esketamine, ketamine, or any of the other ingredients in SPRAVATO®.

If you are not sure if you have any of the above conditions, talk to your healthcare provider before taking SPRAVATO®

Before you take SPRAVATO®, tell your healthcare provider about all of your medical conditions, including if you:

  • have heart or brain problems, including:
    • high blood pressure (hypertension)
    • slow or fast heartbeats that cause shortness of breath, chest pain, lightheadedness, or fainting
    • history of heart attack
    • history of stroke
    • heart valve disease or heart failure
    • history of brain injury or any condition where there is increased pressure in the brain
  • have liver problems
  • have ever had a condition called "psychosis" (see, feel, or hear things that are not there, or believe in things that are not true).
  • are pregnant or plan to become pregnant. SPRAVATO® may harm your baby. You should not take SPRAVATO® if you are pregnant.
    • Tell your healthcare provider right away if you become pregnant during treatment with SPRAVATO®.
    • If you are able to become pregnant, talk to your healthcare provider about methods to prevent pregnancy during treatment with SPRAVATO®.
    • There is a pregnancy registry for women who are exposed to SPRAVATO® during pregnancy. The purpose of the registry is to collect information about the health of women exposed to SPRAVATO® and their baby. If you become pregnant during treatment with SPRAVATO®, talk to your healthcare provider about registering with the National Pregnancy Registry for Antidepressants at 1-844-405-6185 or online at https://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/antidepressants/.
  • are breastfeeding or plan to breastfeed. You should not breastfeed during treatment with SPRAVATO®.

Tell your healthcare provider about all the medicines that you take, including prescription and over-the-counter medicines, vitamins and herbal supplements. Taking SPRAVATO® with certain medicine may cause side effects.

Especially tell your healthcare provider if you take central nervous system (CNS) depressants, psychostimulants, or monoamine oxidase inhibitors (MAOIs) medicine. Keep a list of them to show to your healthcare provider and pharmacist when you get a new medicine.

How will I take SPRAVATO®?

  • You will take SPRAVATO nasal spray yourself, under the supervision of a healthcare provider in a healthcare setting. Your healthcare provider will show you how to use the SPRAVATO® nasal spray device.
  • Your healthcare provider will tell you how much SPRAVATO® you will take and when you will take it.
  • Follow your SPRAVATO® treatment schedule exactly as your healthcare provider tells you to.
  • During and after each use of the SPRAVATO® nasal spray device, you will be checked by a healthcare provider who will decide when you are ready to leave the healthcare setting.
  • You will need to plan for a caregiver or family member to drive you home after taking SPRAVATO®.
  • If you miss a SPRAVATO® treatment, your healthcare provider may change your dose and treatment schedule.
  • Some people taking SPRAVATO® get nausea and vomiting. You should not eat for at least 2 hours before taking SPRAVATO® and not drink liquids at least 30 minutes before taking SPRAVATO®.
  • If you take a nasal corticosteroid or nasal decongestant medicine take these medicines at least 1 hour before taking SPRAVATO®.

What should I avoid while taking SPRAVATO?

Do not drive, operate machinery, or do anything where you need to be completely alert after taking SPRAVATO®. Do not take part in these activities until the next day following a restful sleep. See "What is the most important information I should know about SPRAVATO®?"

What are the possible side effects of SPRAVATO®?

SPRAVATO® may cause serious side effects including:

See "What is the most important information I should know about SPRAVATO?"

Increased blood pressure. SPRAVATO® can cause a temporary increase in your blood pressure that may last for about 4 hours after taking a dose. Your healthcare provider will check your blood pressure before taking SPRAVATO® and for at least 2 hours after you take SPRAVATO®. Tell your healthcare provider right away if you get chest pain, shortness of breath, sudden severe headache, change in vision, or seizures after taking SPRAVATO®.  

Problems with thinking clearly. Tell your healthcare provider if you have problems thinking or remembering.

Bladder problems. Tell your healthcare provider if you develop trouble urinating, such as a frequent or urgent need to urinate, pain when urinating, or urinating frequently at night.

The most common side effects of SPRAVATO when used along with an antidepressant taken by mouth include:

•         feeling disconnected from yourself, your
          thoughts, feelings and things around you

•         dizziness          

•         nausea

•         feeling sleepy

•         spinning sensation

•         decreased feeling of sensitivity (numbness)

•         feeling anxious

•         lack of energy

•         increased blood pressure

•         vomiting

•         feeling drunk

•         feeling very happy or excited

If these common side effects occur, they usually happen right after taking SPRAVATO and go away the same day.

These are not all the possible side effects of SPRAVATO®.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1‑800‑FDA‑1088.

Please see full Prescribing Information, including Boxed WARNINGS, and Medication Guide for SPRAVATO® and discuss any questions you may have with your healthcare provider.

cp-170363v3

INVEGA® IMPORTANT SAFETY INFORMATION

INDICATIONS

INVEGA HAFYERA® (6-month paliperidone palmitate) is a prescription medicine given by injection every 6 months by a healthcare professional and used to treat schizophrenia. INVEGA HAFYERA® is used in adults who have been treated with either:

  • INVEGA SUSTENNA® (paliperidone palmitate) a 1-time-each-month paliperidone palmitate extended-release injectable suspension for at least 4 months
  • INVEGA TRINZA® (paliperidone palmitate) a 1-time-every-3-months paliperidone palmitate extended-release injectable suspension for at least 3 months

INVEGA TRINZA® is a prescription medicine given by injection every 3 months by a healthcare professional and used to treat schizophrenia. INVEGA TRINZA® is used in people who have been adequately treated with INVEGA SUSTENNA® for at least 4 months.

INVEGA SUSTENNA® is a prescription medicine given by injection by a healthcare professional.
INVEGA SUSTENNA® is used to treat schizophrenia in adults.

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about INVEGA HAFYERA®,
INVEGA TRINZA® and INVEGA SUSTENNA®?


INVEGA HAFYERA®, INVEGA TRINZA® and INVEGA SUSTENNA® may cause serious side effects, including:


  • Increased risk of death in elderly people with dementia-related psychosis.
    INVEGA HAFYERA®, INVEGA TRINZA® and INVEGA SUSTENNA® increase the risk of death in elderly people who have lost touch with reality (psychosis) due to confusion and memory loss (dementia). INVEGA HAFYERA®, INVEGA TRINZA® and INVEGA SUSTENNA® are not for the treatment of people with dementia-related psychosis.

 

Do not receive INVEGA HAFYERA®, INVEGA TRINZA® or INVEGA SUSTENNA® if you are allergic to paliperidone, paliperidone palmitate, risperidone, or any of the ingredients in INVEGA HAFYERA®, INVEGA TRINZA® or INVEGA SUSTENNA®. See the end of the Patient Information leaflet in the full Prescribing Information for a complete list of INVEGA HAFYERA®, INVEGA TRINZA® and INVEGA SUSTENNA® ingredients.

Before you receive INVEGA HAFYERA®, INVEGA TRINZA® or INVEGA SUSTENNA®, tell your healthcare professional about all your medical conditions, including if you: 

  • have had Neuroleptic Malignant Syndrome (NMS)
  • have or have had heart problems, including a heart attack, heart failure, abnormal heart rhythm, or long QT syndrome
  • have or have had low levels of potassium or magnesium in your blood
  • have or have had uncontrolled movements of your tongue, face, mouth, or jaw (tardive dyskinesia)
  • have or have had kidney or liver problems
  • have diabetes or have a family history of diabetes
  • have Parkinson's disease or a type of dementia called Lewy Body Dementia
  • have had a low white blood cell count
  • have had problems with dizziness or fainting or are being treated for high blood pressure
  • have or have had seizures or epilepsy
  • have any other medical conditions
  • are pregnant or plan to become pregnant. It is not known if INVEGA HAFYERA®, INVEGA TRINZA® or INVEGA SUSTENNA® will harm your unborn baby
    • If you become pregnant while taking INVEGA HAFYERA®, INVEGA TRINZA® or INVEGA SUSTENNA®, talk to your healthcare professional about registering with the National Pregnancy Registry for Atypical Antipsychotics. You can register by calling 1-866-961-2388 or visit http://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry.
    • Infants born to women who are treated with INVEGA HAFYERA®, INVEGA TRINZA® or INVEGA SUSTENNA® may experience symptoms such as tremors, irritability, excessive sleepiness, eye twitching, muscle spasms, decreased appetite, difficulty breathing, or abnormal movement of arms and legs. Let your healthcare professional know if these symptoms occur.
  • are breastfeeding or plan to breastfeed. INVEGA HAFYERA®, INVEGA TRINZA® or INVEGA SUSTENNA® can pass into your breast milk. Talk to your healthcare professional about the best way to feed your baby if you receive INVEGA HAFYERA®, INVEGA TRINZA® or INVEGA SUSTENNA®

Tell your healthcare professional about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. INVEGA HAFYERA®, INVEGA TRINZA® and INVEGA SUSTENNA® may affect the way other medicines work, and other medicines may affect how INVEGA HAFYERA®, INVEGA TRINZA® and INVEGA SUSTENNA® works.

Your healthcare provider can tell you if it is safe to receive INVEGA HAFYERA®, INVEGA TRINZA® or INVEGA SUSTENNA® with your other medicines. Do not start or stop any medicines during treatment with INVEGA HAFYERA®, INVEGA TRINZA® or INVEGA SUSTENNA® without talking to your healthcare provider first. Know the medicines you take. Keep a list of them to show to your healthcare professional or pharmacist when you get a new medicine.

Patients (particularly the elderly) taking antipsychotics with certain health conditions or those on long-term therapy should be evaluated by their healthcare professional for the potential risk of falls.

How will I receive INVEGA HAFYERA®, INVEGA TRINZA® or INVEGA SUSTENNA®?

  • Follow your treatment schedule exactly as your healthcare provider tells you to.
  • Your healthcare provider will tell you how much you will receive and when you will receive it.

What should I avoid while receiving INVEGA HAFYERA®, INVEGA TRINZA® or INVEGA SUSTENNA®?

  • INVEGA HAFYERA®, INVEGA TRINZA® and INVEGA SUSTENNA® may affect your ability to make decisions, think clearly, or react quickly. Do not drive, operate heavy machinery, or do other dangerous activities until you know how INVEGA HAFYERA®, INVEGA TRINZA® or INVEGA SUSTENNA® affects you.
  • Avoid getting overheated or dehydrated.

INVEGA HAFYERA®, INVEGA TRINZA® and INVEGA SUSTENNA® may cause serious side effects, including:

  • See "What is the most important information I should know about INVEGA HAFYERA®, INVEGA TRINZA® and INVEGA SUSTENNA®?"
  • stroke in elderly people (cerebrovascular problems) that can lead to death
  • Neuroleptic Malignant Syndrome (NMS). NMS is a rare but very serious problem that can happen in people who receive INVEGA HAFYERA®, INVEGA TRINZA® or INVEGA SUSTENNA®. NMS can cause death and must be treated in a hospital. Call your healthcare professional right away if you become severely ill and have any of these symptoms: high fever; severe muscle stiffness; confusion; loss of consciousness; changes in your breathing, heartbeat, and blood pressure.
  • problems with your heartbeat. These heart problems can cause death. Call your healthcare professional right away if you have any of these symptoms: passing out or feeling like you will pass out, dizziness, or feeling as if your heart is pounding or missing beats.
  • uncontrolled movements of your tongue, face, mouth, or jaw (tardive dyskinesia)
  • metabolic changes. Metabolic changes may include high blood sugar (hyperglycemia), diabetes mellitus and changes in the fat levels in your blood (dyslipidemia), and weight gain.
  • low blood pressure and fainting
  • changes in your blood cell counts
  • high level of prolactin in your blood (hyperprolactinemia). INVEGA HAFYERA®, INVEGA TRINZA® or INVEGA SUSTENNA® may cause a rise in the blood levels of a hormone called prolactin (hyperprolactinemia) that may cause side effects including missed menstrual periods, leakage of milk from the breasts, development of breasts in men, or problems with erection.
  • problems thinking clearly and moving your body
  • seizures
  • difficulty swallowing that can cause food or liquid to get into your lungs
  • prolonged or painful erection lasting more than 4 hours. Call your healthcare professional or go to your nearest emergency room right away if you have an erection that lasts more than 4 hours.
  • problems with control of your body temperature, especially when you exercise a lot or spend time doing things that make you warm. It is important for you to drink water to avoid dehydration.

The most common side effects of INVEGA HAFYERA® include: injection site reactions, weight gain, headache, upper respiratory tract infections, feeling restlessness or difficulty sitting still, slow movements, tremors, stiffness and shuffling walk.

The most common side effects of INVEGA TRINZA® include: injection site reactions, weight gain, headache, upper respiratory tract infections, feeling restlessness or difficulty sitting still, slow movements, tremors, stiffness and shuffling walk.

The most common side effects of INVEGA SUSTENNA® include: injection site reactions; sleepiness or drowsiness; dizziness; feeling of inner restlessness or needing to be constantly moving; abnormal muscle movements, including tremor (shaking), shuffling, uncontrolled involuntary movements, and abnormal movements of your eyes.

Tell your healthcare professional if you have any side effect that bothers you or does not go away. These are not all the possible side effects of INVEGA HAFYERA®, INVEGA TRINZA® or INVEGA SUSTENNA®. For more information, ask your healthcare professional or pharmacist.

Call your healthcare professional for medical advice about side effects. You may report side effects of prescription drugs to the FDA at 1-800-FDA-1088.

General information about the safe and effective use of INVEGA HAFYERA®, INVEGA TRINZA® or INVEGA SUSTENNA®

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use INVEGA HAFYERA®, INVEGA TRINZA® or INVEGA SUSTENNA® for a condition for which it was not prescribed. You can ask your pharmacist or healthcare professional for information about INVEGA HAFYERA®, INVEGA TRINZA® or INVEGA SUSTENNA® that is written for healthcare professionals.

For more information, go to www.invegahafyera.com, www.invegatrinza.com or www.invegasustenna.com or call 1-800-526-7736.

Please click to read the full Prescribing Information, including Boxed WARNING, for INVEGA HAFYERA®, INVEGA TRINZA® and INVEGA SUSTENNA® and discuss any questions you have with your healthcare professional.

cp-256259v4

ABOUT JOHNSON & JOHNSON
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and where solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity.

Learn more at http://www.jnj.com or at www.innovativemedicine.jnj.com

Follow us at @JanssenUS and @JNJInnovMed.

Janssen Research & Development, LLC and Janssen Biotech, Inc. are Johnson & Johnson companies. 

Cautions Concerning Forward-Looking Statements
This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding product development and the potential benefits and treatment impact of nipocalimab. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Research & Development, LLC, Janssen Biotech, Inc. and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. None of Janssen Research & Development, LLC, Janssen Biotech, Inc. nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.

  1. Correll C, Solmi, M, Croatto G, et al. Mortality in people with schizophrenia: a systematic review and meta-analysis of relative risk and aggravating or attenuating factors. World Psychiatry. 21(2),248–271. doi:10.1002/wps.20994
  2. World Health Organization. Depressive disorder (depression). Accessed October 2024. who.int/news-room/fact-sheets/detail/depression
  3. National Institute of Mental Health. Major depression. Accessed October 2024. nimh.nih.gov/health/statistics/major-depression
  4. Zhdanava M, Pilon D, Ghelerter I, et al. The prevalence and national burden of treatment-resistant depression and major depressive disorder in the United States. J Clin Psychiatry. (2021);82(2):20m13699.
  5. World Health Organization. "Depression: let's talk" says WHO, as depression tops list of causes of ill health. Accessed October 2024. https://www.who.int/news/item/30-03-2017--depression-let-s-talk-says-who-as-depression-tops-list-of-causes-of-ill-health
  6. Sakurai, H, Suzuki, T, Yoshimura, K, et al. Predicting relapse with individual residual symptoms in major depressive disorder: a reanalysis of the STAR*D data. Psychopharmacology. (2017);234(16): 2453–2461 . https://doi.org/10.1007/s00213-017-4634-5
  7. Psychopharmacology Institute. Understanding the relationship between insomnia disorder and MDD.. Accessed October 2024. https://psychopharmacologyinstitute.com/section/understanding-the-relationship-between-insomnia-disorder-and-mdd-2765-5602 
  8. Taddei-Allen, P. Economic burden and managed care considerations for the treatment of insomnia. Am J Manag Care. (2020);26:S91-S96. doi.org/10.37765/ajmc.2020.43008
  9. World Health Organization. Schizophrenia. Accessed October 2024. https://www.who.int/news-room/fact-sheets/detail/schizophrenia
  10. Regier DA, Farmer ME, Rae DS, et al. One–month prevalence of mental disorders in the United States and sociodemographic characteristics: the epidemiologic catchment area study. Acta Psychiatr Scand. (1993);88(1):35-47. doi:10.1111/j.1600-0447.1993.tb03411.x
  11. US Census Bureau. 2010 US Census. Accessed October 2024. https://www.census.gov/topics/population/data.html
  12. Andreasen N, Nopoulos P, Magnotta V, et al. Progressive brain change in schizophrenia: a prospective longitudinal study of first-episode schizophrenia. Biol Psychiatry. (2011);70(7):672-679. doi:10.1016/j.biopsych.2011.05.017
  13. Higashi K, Medic G, Littlewood K, et al. Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systemic literature review. Ther Adv Psychopharmacol. (2013);3(4):200-218. doi:10.1177/2045125312474019
  14. American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia. Accessed October 2024.  https://psychiatryonline.org/doi/pdf/10.1176/appi.books.9780890424841
  15. American Psychiatric Association. APA releases new practice guideline on treatment of patients with schizophrenia. Accessed October 2024.  https://www.psychiatry.org/newsroom/news-releases/apa-releases-new-practice-guideline-on-treatment-of-patients-with-schizophrenia
  16. National Council for Mental Wellbeing. Guide to long-acting medications. Accessed October 2024. https://www.thenationalcouncil.org/topics/long-acting-medications/

© Johnson & Johnson 2024. All rights reserved.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/johnson--johnson-highlights-innovative-neuropsychiatry-portfolio-and-pipeline-at-psych-congress-302285418.html

SOURCE Johnson & Johnson

FAQ

What new data did JNJ present about SPRAVATO at Psych Congress 2024?

JNJ presented five-year real-world safety data from nearly 35,000 adults treated with SPRAVATO®, reinforcing its well-studied safety profile in treatment-resistant depression.

How many research abstracts did JNJ present at Psych Congress 2024?

Johnson & Johnson presented 23 abstracts featuring new real-world and clinical trial data from its neuropsychiatry portfolio and pipeline.

What were the key findings of JNJ's schizophrenia study presented at Psych Congress 2024?

The study analyzed over 30,000 adults with schizophrenia, highlighting the link between symptom relapse and risk of death, with patients facing 15-20 years shorter life expectancy compared to the general population.

Johnson & Johnson

NYSE:JNJ

JNJ Rankings

JNJ Latest News

JNJ Stock Data

353.35B
2.41B
0.09%
72.68%
0.78%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States of America
NEW BRUNSWICK